Last edition
News about "Daiichi Sankyo"
AstraZeneca Completes USD 2B Equity Investment in Summit Therapeutics
AstraZeneca has completed its USD 2 billion equity investment in Summit Therapeutics to advance ivonescimab-based cancer treatment combinations.
Daiichi Sankyo | 06/10/2026 | By News Bureau
AstraZeneca and Daiichi Sankyo Partner with Summit on Datroway
AstraZeneca and Daiichi Sankyo enter clinical collaboration with Summit Therapeutics to evaluate Datroway in combination with ivonescimab across multiple tumor types.
Daiichi Sankyo | 05/10/2026 | By News Bureau
Japan Approves Enhertu and Datroway for New First-Line Metastatic Breast Cancer Indications
Japan has approved new first-line metastatic breast cancer indications for Daiichi Sankyo’s Enhertu and Datroway, expanding treatment options for patients with HER2-positive and triple-negative breast cancer.
Daiichi Sankyo | 17/09/2026 | By News Bureau | 417
AstraZeneca, Daiichi Sankyo's Enhertu Shows Superior PFS in First-Line HER2-Mutant NSCLC
DESTINY-Lung04 results showed Enhertu delivered a median PFS of 14.3 months versus 8.3 months with pembrolizumab plus chemotherapy in first-line HER2-mutant advanced NSCLC.
Daiichi Sankyo | 16/09/2026 | By News Bureau
Tokyo Court Dismisses NTK's JPY 203.3 Billion Claims Against Daiichi Sankyo
The Tokyo District Court has dismissed all claims by Northern TK Venture seeking JPY 203.3 billion in damages and other relief from Daiichi Sankyo.
Daiichi Sankyo | 11/09/2026 | By News Bureau | 103
The European Union (EU) has approved Enhertu plus pertuzumab as a new first-line regimen for HER2-positive metastatic breast cancer, reducing progression or death risk by 44 percent.
Daiichi Sankyo | 02/09/2026 | By News Bureau
Daiichi Sankyo Begins Clinical Development of CD25-Targeted ADC DS1025
Daiichi Sankyo advances DS1025 into clinical development as a potential first-in-class CD25-targeted Antibody Drug Conjugate (ADC) for patients with advanced solid tumors.
Daiichi Sankyo | 01/09/2026 | By News Bureau
The first patient has been dosed in the global Phase 3 TROPION-Urothelial04 trial, advancing evaluation of Datroway-based therapies for high-risk muscle-invasive urothelial cancer.
Daiichi Sankyo | 27/08/2026 | By News Bureau
Enhertu Plus Pertuzumab Approved in China for First-Line HER2-Positive Metastatic Breast Cancer
Enhertu plus pertuzumab has been approved in China as first-line treatment for HER2-positive metastatic breast cancer, based on positive phase 3 results.
Daiichi Sankyo | 13/08/2026 | By News Bureau | 139
Innovent and Daiichi Sankyo Partner for Vanflyta Commercialisation in China
Innovent Biologics and Daiichi Sankyo have entered an exclusive agreement to commercialise Vanflyta in China, expanding access for FLT3-ITD positive AML patients.
Daiichi Sankyo | 11/08/2026 | By News Bureau | 109
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy